Preclinical study reveals gold nanoparticle-coated bacteria drive tumor-selective catalytic cell death in mice, highlighting a novel biohybrid strategy for targeted cancer therapy.
Catalytic nanomedicine represents an attractive therapeutic approach for cancer therapy while heavily relying on the catalytic activity and tumor selectivity of the catalyst. Here, a novel catalytic biohybrid (“bacterobot”) of gold nanoparticle-coated electroactive bacterium is developed for enhanced catalytic cancer therapy. The electroactive G. sulfurreducens, for the first time used in cancer therapy, turbocharges the multienzyme-like catalytic activities of biosynthetic gold nanoparticles via cascade catalytic reactions to produce abundant reactive oxygen species to induce apoptosis and pyroptosis of tumor cells. Distinctive tumor accumulation and a tumor inhibition rate of 68% were achieved with single-dose intravenous injection of biohybrids in 4T1 tumor-bearing mice. Overall, the bacterobot biohybrid therapy demonstrates a high degree of therapeutic selectivity to tumor tissues and consequent excellent therapeutic efficacy and systemic biosafety, signifying the potential to create a paradigm shift in the way cancers are treated.
No takes yet. Share an insight, caveat, or question.
Zong et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: